---
title: "板塊更新：醫療保健類股票在週一下午出現回落"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277511276.md"
description: "醫療股在週一下跌，紐約證券交易所醫療保健指數和 State Street 醫療保健精選行業 SPDR ETF（XLV）下跌了 1.2%。iShares 生物技術 ETF（IBB）下降了 1.1%。值得注意的是，uniQure（QURE）的股價暴跌 33%，因為 FDA 認為他們的試驗數據不足以支持 AMT-130 的市場申請。Zoetis（ZTS）宣佈以 1.6 億美元收購 Neogen（NEOG）的動物基因組業務，而 Gyre Therapeutics（GYRE）的股價在達成以 3 億美元股票收購 Cullgen 的協議後上漲了 7.4%"
datetime: "2026-03-02T19:02:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277511276.md)
  - [en](https://longbridge.com/en/news/277511276.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277511276.md)
---

# 板塊更新：醫療保健類股票在週一下午出現回落

02:02 PM EST, 03/02/2026 (MT Newswires) -- Health care stocks declined Monday afternoon with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each dropping 1.2%.

The iShares Biotechnology ETF (IBB) shed 1.1%.

In corporate news, uniQure (QURE) shares tumbled 33% after the US Food and Drug Administration said data from the company's Phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.

Zoetis ( ZTS ) agreed to buy Neogen's (NEOG) animal genomics business for $160 million. Neogen shares fell 0.7%, and Zoetis ( ZTS ) dropped 2%.

Gyre Therapeutics ( GYRE ) shares climbed 7.4% after the company agreed to acquire clinical-stage biopharmaceutical company Cullgen for $300 million in stock.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### 相關股票

- [QURE.US](https://longbridge.com/zh-HK/quote/QURE.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [NEOG.US](https://longbridge.com/zh-HK/quote/NEOG.US.md)
- [LABD.US](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [IDNA.US](https://longbridge.com/zh-HK/quote/IDNA.US.md)
- [IHI.US](https://longbridge.com/zh-HK/quote/IHI.US.md)
- [GYRE.US](https://longbridge.com/zh-HK/quote/GYRE.US.md)
- [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [XHE.US](https://longbridge.com/zh-HK/quote/XHE.US.md)

## 相關資訊與研究

- [巨生醫細胞治療產品獲 SelectUSA Tech 醫療領域前 8 強 有助美國市場佈局](https://longbridge.com/zh-HK/news/282988767.md)
- [藥廠 AI 合作潮！諾和諾德攜手 OpenAI 股價走揚](https://longbridge.com/zh-HK/news/282755292.md)
- [巨生醫細胞治療產品 MPB-2354 獲選 SelectUSA Tech 醫療領域前八強](https://longbridge.com/zh-HK/news/282972944.md)
- [鉅亨速報 - Factset 最新調查：Summit Therapeutics Inc(SMMT-US) EPS 預估上修至-1.2 元，預估目標價為 33.00 元](https://longbridge.com/zh-HK/news/282998825.md)
- [鉅亨速報 - Factset 最新調查：美敦力公司 (MDT-US) EPS 預估下修至 5.52 元，預估目標價為 111.00 元](https://longbridge.com/zh-HK/news/282861471.md)